Sugi Predict

Sugi Predict / Compounds / SCHEMBL2174089

SCHEMBL2174089

SCHEMBL2174089

C[C@@]1(C(=O)N2CCN(c3ccccc3)CC2)[C@@H](C(=O)NO)C[C@H](Sc2ccccc2)CN1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ ADAM10 O14672 15/20 0.41
▸ MMP2 P08253 15/20 0.41
▸ ERBB2 P04626 14/20 0.41
▸ MMP9 P14780 10/20 0.39
▸ MMP3 P08254 6/20 0.38
▸ POLB P06746 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2174446 0.83 ADAM10 (0.43) LMNAALDH1A1ADAM10MMP2ERBB2
SCHEMBL2174042 0.81 ADAM10 (0.44) LMNAALDH1A1ADAM10MMP2ERBB2
SCHEMBL2172274 0.80 ADAM10 (0.41) LMNAALDH1A1ADAM10MMP2ERBB2
SCHEMBL2176839 0.80 ADAM10 (0.57) LMNAALDH1A1ADAM10MMP2ERBB2
SCHEMBL2173630 0.79 ADAM10 (0.58) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL2174249 0.79 ADAM10 (0.58) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL2172843 0.79 ADAM10 (0.40) LMNAALDH1A1ADAM10MMP2ERBB2
SCHEMBL2171783 0.78 ADAM10 (0.40) LMNAALDH1A1ADAM10MMP2ERBB2
SCHEMBL2172691 0.78 ADAM10 (0.40) LMNAALDH1A1ADAM10MMP2ERBB2
SCHEMBL2176417 0.78 ADAM10 (0.59) ADAM10MMP2ERBB2MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US claimed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US claimed
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 LMNA 2321/4885ALDH1A1 673/4885ADAM10 25/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 LMNA 2198/4885ALDH1A1 497/4885ADAM10 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.